Literature DB >> 27467934

Notching tumor: Signaling through Notch receptors improves antitumor T cell immunity.

Roman Uzhachenko1, Anil Shanker2.   

Abstract

Notch signaling is crucial for lymphocyte effector and memory differentiation. While tumor suppress Notch signaling in antitumor lymphocytes, recent studies show that the pharmacological Delta-like ligand-1 multivalent cluster or proteasome inhibitor bortezomib can restore Notch-NF-κB signaling in T cells of tumor-bearing hosts with a potential to overcome cancer cell resistance to therapy.

Entities:  

Keywords:  Adoptive T cell therapy; Delta-like ligands; Notch signaling; antitumor immunity; bortezomib; cancer immunotherapy; immunosuppression

Year:  2016        PMID： 27467934      PMCID： PMC4910711          DOI： 10.1080/2162402X.2015.1122864

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Canonical and non-canonical Notch signaling in CD4⁺ T cells.

Authors:  Lisa M Minter; Barbara A Osborne
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 2.  Notch signaling in the immune system.

Authors:  Freddy Radtke; Nicolas Fasnacht; H Robson Macdonald
Journal:  Immunity       Date:  2010-01-29       Impact factor: 31.745

Review 3.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Authors:  William Pao; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

4.  Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth.

Authors:  Yuhui Huang; Luping Lin; Anil Shanker; Anshu Malhotra; Li Yang; Mikhail M Dikov; David P Carbone
Journal:  Cancer Res       Date:  2011-08-08       Impact factor: 12.701

5.  Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy.

Authors:  Asel K Biktasova; Duafalia F Dudimah; Roman V Uzhachenko; Kyungho Park; Anwari Akhter; Rajeswara R Arasada; Jason V Evans; Sergey V Novitskiy; Elena E Tchekneva; David P Carbone; Anil Shanker; Mikhail M Dikov
Journal:  Cancer Res       Date:  2015-09-24       Impact factor: 12.701

6.  Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians.

Authors:  Yongsheng Wang; Gerald Schmid-Bindert; Caicun Zhou
Journal:  Ther Adv Med Oncol       Date:  2012-01       Impact factor: 8.168

7.  Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.

Authors:  Anil Shanker; Samuel T Pellom; Duafalia F Dudimah; Menaka C Thounaojam; Rachel L de Kluyver; Alan D Brooks; Hideo Yagita; Daniel W McVicar; William J Murphy; Dan L Longo; Thomas J Sayers
Journal:  Cancer Res       Date:  2015-10-22       Impact factor: 12.701

Review 8.  Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think.

Authors:  Camille Lobry; Philmo Oh; Iannis Aifantis
Journal:  J Exp Med       Date:  2011-09-26       Impact factor: 14.307

Review 9.  Non-canonical notch signaling in cancer and immunity.

Authors:  Furkan Ayaz; Barbara A Osborne
Journal:  Front Oncol       Date:  2014-12-04       Impact factor: 6.244

10.  Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.

Authors:  Menaka C Thounaojam; Duafalia F Dudimah; Samuel T Pellom; Roman V Uzhachenko; David P Carbone; Mikhail M Dikov; Anil Shanker
Journal:  Oncotarget       Date:  2015-10-20
  10 in total
  2 in total

Review 1.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

2.  Notch as an Immunologic Basis of Cancer Disparities.

Authors:  Portia LaLiah Thomas; Anil Shanker
Journal:  Cancer Health Disparities       Date:  2019-08-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.